Skip to content

Study · Animal study (in vivo) · mouse · 2021

11 results

The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.

Sun H, Wang J, Guo L, Wang Y, Zhang J, Wang J, Quan M, Li B

Journal of neuroimmunology24 Oct 2020Cited by 3 (Europe PMC)

PMID33176238 (opens in a new tab)DOI10.1016/j.jneuroim.2020.577429 (opens in a new tab)PepBankPUB-33176238
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In EAE mice, NAD+ and atorvastatin combined at half their optimal dosages reduced severity more than atorvastatin alone.

    In plain wordsIn mice, NAD+ and atorvastatin combined at half their optimal dosages reduced disease severity more than atorvastatin alone.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseEAE severity versus atorvastatin alone
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Comparator
    Atorvastatin alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our results showed that the combined treatment of these two drugs at half of their optimal dosages had synergistic effect to alleviate the severity of EAE in mice than treatment with each alone.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

Studies that did not test the peptide alone10

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  1. 02AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In EAE mice, NAD+ and atorvastatin combined at half their optimal dosages reduced severity more than NAD+ alone.

    In plain wordsIn mice, NAD+ and atorvastatin combined at half their optimal dosages reduced disease severity more than NAD+ alone.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseEAE severity versus NAD+ alone
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Comparator
    NAD+ alone
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Our results showed that the combined treatment of these two drugs at half of their optimal dosages had synergistic effect to alleviate the severity of EAE in mice than treatment with each alone.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  2. 03AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In EAE mice, atorvastatin plus NAD+ relieved clinical signs.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ relieved clinical signs.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseClinical signs
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The combined treatment of EAE mice with atorvastatin plus NAD+ relieved the clinical signs and histologic changes, increased the proportion of Treg cells, attenuated IL-17 production, reduced proinflammatory cytokine secretion of Th17 cells, and increased cytokine secretion of Treg cells.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  3. 04AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In EAE mice, atorvastatin plus NAD+ relieved histologic changes.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ reduced tissue changes.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseHistologic changes
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The combined treatment of EAE mice with atorvastatin plus NAD+ relieved the clinical signs and histologic changes, increased the proportion of Treg cells, attenuated IL-17 production, reduced proinflammatory cytokine secretion of Th17 cells, and increased cytokine secretion of Treg cells.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  4. 05AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, atorvastatin plus NAD+ increased the proportion of Treg cells.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ increased the proportion of Treg cells.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseTreg cell proportion
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The combined treatment of EAE mice with atorvastatin plus NAD+ relieved the clinical signs and histologic changes, increased the proportion of Treg cells, attenuated IL-17 production, reduced proinflammatory cytokine secretion of Th17 cells, and increased cytokine secretion of Treg cells.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  5. 06AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, atorvastatin plus NAD+ reduced IL-17 production.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ reduced IL-17 production.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseIL-17 production
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    The combined treatment of EAE mice with atorvastatin plus NAD+ relieved the clinical signs and histologic changes, increased the proportion of Treg cells, attenuated IL-17 production, reduced proinflammatory cytokine secretion of Th17 cells, and increased cytokine secretion of Treg cells.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  6. 07AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, atorvastatin plus NAD+ reduced proinflammatory cytokine secretion by Th17 cells.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ reduced inflammatory cytokine secretion by Th17 cells.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseTh17 proinflammatory cytokine secretion
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    The combined treatment of EAE mice with atorvastatin plus NAD+ relieved the clinical signs and histologic changes, increased the proportion of Treg cells, attenuated IL-17 production, reduced proinflammatory cytokine secretion of Th17 cells, and increased cytokine secretion of Treg cells.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  7. 08AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, atorvastatin plus NAD+ increased cytokine secretion by Treg cells.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ increased cytokine secretion by Treg cells.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseTreg cytokine secretion
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The combined treatment of EAE mice with atorvastatin plus NAD+ relieved the clinical signs and histologic changes, increased the proportion of Treg cells, attenuated IL-17 production, reduced proinflammatory cytokine secretion of Th17 cells, and increased cytokine secretion of Treg cells.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  8. 09AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, combined atorvastatin and NAD+ reduced P38 MAPK phosphorylation.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ reduced P38 MAPK phosphorylation.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseP38 MAPK phosphorylation
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    In addition, the combined treatment also diminished phosphorylation of both P38 MAPK and ERK, while elevated SIRT1 expression.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  9. 10AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, combined atorvastatin and NAD+ reduced ERK phosphorylation.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ reduced ERK phosphorylation.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseERK phosphorylation
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    In addition, the combined treatment also diminished phosphorylation of both P38 MAPK and ERK, while elevated SIRT1 expression.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  10. 11AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In EAE mice, combined atorvastatin and NAD+ increased SIRT1 expression.

    In plain wordsIn mice with EAE, atorvastatin plus NAD+ increased SIRT1 expression.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseSIRT1 expression
    Study

    mousen: not reported in source

    C57BL/6 experimental autoimmune encephalomyelitis mice
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    In addition, the combined treatment also diminished phosphorylation of both P38 MAPK and ERK, while elevated SIRT1 expression.
    1 context sentence
    Summary · context
    Since combination therapy can exhibit more beneficial effects than monotherapy, we observed the protective effects of combined treatment of atorvastatin and NAD+ in EAE mice.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.